EGFR and non-small cell lung carcinoma: With development of molecular diagnosis, tyrosine kinase inhibitors (TKIs) have become the standard therapy for NSCLC patients harboring EGFR or ALK alterations over the past two decades and brought great clinical benefit for NSCLC patients.